Receiver operating characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as a predictor of mortality at 30 days.

<p>Receiver operating characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as a predictor of mortality at 30 days.</p

Survival curves at 30 days using serum caspase-cleaved cytokeratin (CCCK)-18 levels higher or lower than 201 u/L.

<p>Survival curves at 30 days using serum caspase-cleaved cytokeratin (CCCK)-18 levels higher or lower than 201 u/L.</p

Comparison of computer tomography findings between non-surviving and surviving patients with traumatic brain injury.

<p>Comparison of computer tomography findings between non-surviving and surviving patients with traumatic brain injury.</p

Comparison of clinical and biochemical characteristics between non-surviving and surviving patients with traumatic brain injury.

<p>Data are shown as median (percentile 25^th-75^th) or number (%); APACHE II = Acute Physiology and Chronic Health Evaluation; aPTT = activated partial thromboplastin time; CCCK = caspase-cleaved cytokeratin; CPP = cerebral perfusion pressure; ICP = intracranial pressure; INR = international normalized ratio; ISS = Injury Severity Score; PaO₂ = pressure of arterial oxygen; FIO₂ = fraction inspired oxygen; PaCO₂ = pressure of arterial carbon dioxide</p><p>Comparison of clinical and biochemical characteristics between non-surviving and surviving patients with traumatic brain injury.</p

Multiple binomial logistic regression analysis to predict 30-day mortality.

<p>GCS Glasgow Coma Scale; CCCK = caspase-cleaved cytokeratin; APACHE II = Acute Physiology and Chronic Health Evaluation</p><p>Multiple binomial logistic regression analysis to predict 30-day mortality.</p

Receiver operation characteristic analysis using TIMP-1 serum levels as predictor of mortality at 30 days.

<p>Receiver operation characteristic analysis using TIMP-1 serum levels as predictor of mortality at 30 days.</p

Correlation between serum TIMP-1 levels and other baseline clinical and biochemical characteristics.

<p>TIMP =  tissue inhibitor of matrix metalloproteinase; GCS =  Glasgow Coma Scale; TNF  =  tumor necrosis factor; PAI  =  plasminogen activator inhibitor; INR  =  international normalized ratio; aPTT  =  activated partial thromboplastin time; MMP  =  matrix metalloproteinase. Bonferroni correction to control the multiple testing problem (0.05/11 = 0.004) was used. Only <i>P</i>-values lower than 0.004 were considered statistically significant.</p

Multiple binomial logistic regression analysis of variables to predict 30-day mortality.

<p>TIMP  =  tissue inhibitor of matrix metalloproteinase; APACHE II  =  Acute Physiology and Chronic Health Evaluation; GCS Glasgow Coma Scale</p

Baseline clinical and biochemical characteristics of survivor and non-survivor patients.

<p>P 25–75 = percentile 25^th–75^th; PaO₂ = pressure of arterial oxygen/fraction inspired oxygen; FIO₂  =  pressure of arterial oxygen/fraction inspired oxygen; ISS  =  Injury Severity Score; INR  =  international normalized ratio; aPTT  =  activated partial thromboplastin time; APACHE II  =  Acute Physiology and Chronic Health Evaluation; ICP  =  intracranial pressure; CPP  =  cerebral perfusion pressure; TIMP  =  tissue inhibitor of matrix metalloproteinase; MMP  =  matrix metalloproteinase; TNF  =  tumor necrosis factor; PAI  =  plasminogen activator inhibitor</p

Survival curves at 30 days using 220/mL of TIMP-1 serum levels as cut-off.

<p>Survival curves at 30 days using 220/mL of TIMP-1 serum levels as cut-off.</p